Login
$TPST
$0.36 +$0.02 (5.32%) After hours

$TPST SEC Filings

Filed On Filing
13 Nov 2026 8-K: Results of Operations and Financial Condition

Exclusively licensed Senlang’s CD7-Targeted lentiviral in vivo CAR-T platform following initial Phase 1 results with lead BCMA/GPRC5D candidate TPST-4903

13 Nov 2026 QUARTERLY REPORT
12 Nov 2026 8-K: Regulation FD Disclosure; Other Events

Tempest Therapeutics Exercises Option to License Senlang’s CD7-Targeted Lentiviral In Vivo CAR-T Platform Following Initial Phase 1 Results with Lead BCMA/GPRC5D Candidate

10 Nov 2026 8-K: Submission of Matters to a Vote of Security Holders

On November 9, 2026, Tempest Therapeutics, Inc., a Delaware corporation (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). The final results for each of the proposals submitted to a vote of the Company’s...

06 Nov 2026 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

On November 4, 2026, Tempest Therapeutics, Inc., a Delaware corporation (the “Company”), received a letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the l...

03 Nov 2026 Form 3: Horn-Warnock Stephanie, CFO, Treasurer, & Corp Sec.

No securities owned

02 Nov 2026 Form 4: Frederick John W., Director

Granted 25,000 Stock Option (right to buy)

02 Nov 2026 Form 3: Frederick John W., Director

Holds 8,000 shares of Common Stock

02 Nov 2026 FORM ARS
30 Oct 2026 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Chief Financial Officer and Principal Financial and Accounting Officer

26 Oct 2026 Proxy statement: annual meeting on November 9, 2026

CEO pay $2.3M, up 23%

20 Oct 2026 CURRENT REPORT
20 Oct 2026 8-K: Submission of Matters to a Vote of Security Holders; Other Events

The information disclosed in Item 8.01 of this Current Report on Form 8-K is incorporated herein by reference.

19 Oct 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

Brisbane, CA, October 14, 2026 – Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company developing in vivo CAR-T therapies designed to reset dysfunctional immunity in cancer and autoimmune disease, ...

16 Oct 2026 PRELIMINARY PROXY STATEMENT
14 Oct 2026 D
02 Oct 2026 Form 4: Smith Nancy Freda, Director

Granted 25,000 Stock Option (right to buy)

02 Oct 2026 Form 3: Smith Nancy Freda, Director

No securities owned

02 Oct 2026 PROSPECTUS
01 Oct 2026 EFFECT

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support